

Cancel Claims 14 - 24, 26, 28-38, 46-50, 52-53, and 55-65.

H³
1. (amended) A method of measuring expression of a cell-surface molecule on the surface of human blood cells, comprising:
contacting a sample containing human blood cells with a lysosomotropic amine and an antibody specific for said cell-surface molecule; and then
detecting the binding of said antibody to said cells.

A⁴
3. (amended) The method of claim 1, wherein said lysosomotropic amine is selected from the group consisting of chloroquine, hydroxychloroquine, primaquine, and methylamine.

A⁵
6. (amended) The method of claim 1, wherein said antibody is labeled with a fluorophore.

A⁶
9. (amended) The method of claim 8, wherein said fluorophore is conjugated to said antibody at a defined molar ratio.

11. (amended) The method of claim 1, wherein said antibody binding is detected flow cytometrically.

A⁷
12. (amended) The method of claim 11, wherein said lysosomotropic amine is chloroquine and said antibody is conjugated to PE.

13. (amended) The method of claim 12, wherein said antibody is conjugated to PE at a molar ratio of 1:1.

A⁸
39. (amended) A composition for flow cytometric measurement of a cell-surface molecule on human peripheral blood cells, comprising:
a fluorophore-conjugated antibody specific for said cell-surface molecule, and
a lysosomotropic amine.

51. (amended) A kit for flow cytometric measurement of a cell-surface molecule
on the surface of peripheral blood cells, comprising:
a composition according to claim 39, and
an erythrocyte lysing composition.